Výsledky vyhledávání - "Brock Schroeder"

Akademický článek

Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk‐Enhancing Factor in the Pooled Cohort Equation: A Cost‐Effectiveness Analysis Study

Autor: Deo Mujwara, Geoffrey Henno, Stephen T. Vernon, Siyang Peng, Paolo Di Domenico, Brock Schroeder, George B. Busby, Gemma A Figtree, Giordano Bottà

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 12 (2022)

Background Cardiovascular diseases are the leading cause of death in the United States, yet a significant proportion of adults at high risk remain undetected by standard screening practices. Polygenic risk score for coronary artery disease (CAD‐PRS

Externí odkaz: https://doaj.org/article/6be5a33f46524d94b882b807c7254908

Zobrazit plný text záznamu

Akademický článek

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer

Autor: Brock Schroeder, Yi Zhang, Olle Stål, Tommy Fornander, Adam Brufsky, Dennis C. Sgroi, Catherine A. Schnabel

Publikováno v: npj Breast Cancer, Vol 3, Iss 1, Pp 1-3 (2017)

Abstract Patients with early-stage, hormone receptor–positive breast cancer with favorable clinicopathologic features are often not recommended for extended endocrine therapy. However, even patients with T1N0 disease remain at significant risk of d

Externí odkaz: https://doaj.org/article/92e90599335f479b9f2cb277f9642bd4

Zobrazit plný text záznamu

The diagnostic trajectory of infants and children with clinical features of genetic disease

Autor: Brock Schroeder, Nina Gonzaludo, Ryan J. Taft, Kyi-Sin Than, Katie Everson, John W Belmont, Jeff Sullivan

Publikováno v: npj Genomic Medicine, Vol 6, Iss 1, Pp 1-10 (2021)
NPJ Genomic Medicine

We characterized US pediatric patients with clinical indicators of genetic diseases, focusing on the burden of disease, utilization of genetic testing, and cost of care. Curated lists of diagnosis, procedure, and billing codes were used to identify p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e673e790e190753d5df0fe9e506e029b
https://doi.org/10.1038/s41525-021-00260-2

Zobrazit plný text záznamu

Pathogenic fusion detection in solid malignancies utilizing RNA-DNA based comprehensive genomic profiling (CGP) testing

Autor: Brian Piening, Alexa K. Dowdell, Ryan Meng, Ann Vita, Roshanthi K. Weerasinghe, Alisha Stein, Bela Bapat, Brock Schroeder, Shu-Ching Chang, Lauren Harold, Mark Schmidt, Thomas Ward, Josiah Wagner, Stanley Piotrowski, Phillip G. Febbo, Carlo Bruno Bifulco

Publikováno v: Journal of Clinical Oncology. 40:3078-3078

3078 Background: Gene fusions caused by chromosomal rearrangements comprise a key category of oncogenic driver mutations. However, given the diverse array of potentially novel loci where each proto-oncogene can translocate, many assays including DNA-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1544b457868f95f4fb18f52ed1577efb
https://doi.org/10.1200/jco.2022.40.16_suppl.3078

Zobrazit plný text záznamu

Identification of clinically actionable biomarkers via routine comprehensive genomic profiling across a large community health system

Autor: Roshanthi K. Weerasinghe, Ryan Meng, Alexa K. Dowdell, Bela Bapat, Ann Vita, Brock Schroeder, Alisha Stein, Lauren Harold, Mark Schmidt, Shu-Ching Chang, Thomas Ward, Josiah Wagner, Stanley Piotrowski, Phillip G. Febbo, Carlo Bruno Bifulco, Brian Piening

Publikováno v: Journal of Clinical Oncology. 40:e15035-e15035

e15035 Background: Precision therapies and immunotherapies have revolutionized cancer care, with novel genomic biomarker-associated therapies being introduced into clinical practice rapidly. We assessed the utility of comprehensive genomic profiling

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11f63e43b31ba49acd36bb8810513b57
https://doi.org/10.1200/jco.2022.40.16_suppl.e15035

Zobrazit plný text záznamu

Actionability of comprehensive genomic profiling (CGP) compared to single-gene and small panels in patients with advanced/metastatic non-small cell lung cancer (aNSCLC): A real-world study

Autor: Bela Bapat, Connor Sweetnam, Ashleigh McBratney, Monika A. Izano, Brock Schroeder, Sheetal Walters, William Chen, Phillip G. Febbo, Anna B. Berry

Publikováno v: Journal of Clinical Oncology. 40:e21114-e21114

e21114 Background: Biomarker testing for patients with aNSCLC includes testing for specific alterations in single genes, hotspot multigene panels, or CGP. Historically, CGP has been used following progression on early lines of systemic therapy to ide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cf553f79b9e9ccfbc4e6f3e6648a7b17
https://doi.org/10.1200/jco.2022.40.16_suppl.e21114

Zobrazit plný text záznamu

72 Routine use of comprehensive genomic profiling to assess tumor mutational burden across a community health system

Autor: Nancy Biery, Bela Bapat, Alexa K Dowdell, Mary Campbell, David A. Eberhard, Tom Ward, Carlo Bifulco, David Ball, Alisha Stein, Brock Schroeder, Shwetha Pindikuri, Sheila Reynolds, Brian D. Piening, Roshanthi Weerasinghe

Publikováno v: Regular and young investigator award abstracts.

Background Tumor mutational burden (TMB), defined as the average number of somatic mutations per megabase (mut/Mb) of DNA in tumor cells, has emerged as a predictive biomarker for response to immune checkpoint inhibitor (ICI) therapy. With more wides

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7183bae004f76f20e4123278128040ed
https://doi.org/10.1136/jitc-2020-sitc2020.0072

Zobrazit plný text záznamu

Multi-Institutional, Prospective Clinical Utility Study Evaluating the Impact of the 92-Gene Assay (CancerTYPE ID) on Final Diagnosis and Treatment Planning in Patients With Metastatic Cancer With an Unknown or Unclear Diagnosis

Autor: Theresa N. Operana, Anthony R. Victorio, Sachdev P. Thomas, Brock Schroeder, Lauren E. Jacobson, Catherine A. Schnabel, Fadi Braiteh

Publikováno v: JCO Precision Oncology. :1-12

Purpose Metastatic cancers of unknown primary or with unclear diagnoses pose diagnostic and management challenges, often leading to poor outcomes. Studies of the 92-gene assay have demonstrated improved diagnostic accuracy compared with standard path

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f0d9b2969108fb90ddf4a5ef28a4b0
https://doi.org/10.1200/po.17.00145

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání